-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$55.0018.41% Upside
Protagonist Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. has been rated by research analysts at Truist Financial, H.C. Wainwright in the past 90 days.